BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

440 related articles for article (PubMed ID: 17547505)

  • 1. Advanced therapeutic and prophylactic strategies for Epstein-Barr virus infection in immunocompromised patients.
    Okano M; Gross TG
    Expert Rev Anti Infect Ther; 2007 Jun; 5(3):403-13. PubMed ID: 17547505
    [TBL] [Abstract][Full Text] [Related]  

  • 2. B lymphocytes and Epstein-Barr virus: the lesson of post-transplant lymphoproliferative disorders.
    Dolcetti R
    Autoimmun Rev; 2007 Dec; 7(2):96-101. PubMed ID: 18035317
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention and treatment of Epstein-Barr virus (EBV)-associated lymphoproliferative diseases in immune deficient patients.
    Purtilo DT
    AIDS Res; 1986 Dec; 2 Suppl 1():S177-81. PubMed ID: 2435295
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Primary immunodeficiencies predisposed to Epstein-Barr virus-driven haematological diseases.
    Parvaneh N; Filipovich AH; Borkhardt A
    Br J Haematol; 2013 Sep; 162(5):573-86. PubMed ID: 23758097
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epstein-Barr virus infections: prospects for treatment.
    Gershburg E; Pagano JS
    J Antimicrob Chemother; 2005 Aug; 56(2):277-81. PubMed ID: 16006448
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathogenesis of chronic active Epstein-Barr virus infection: is this an infectious disease, lymphoproliferative disorder, or immunodeficiency?
    Kimura H
    Rev Med Virol; 2006; 16(4):251-61. PubMed ID: 16791843
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epstein-Barr virus--associated diseases in humans.
    Kawa K
    Int J Hematol; 2000 Feb; 71(2):108-17. PubMed ID: 10745621
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunodeficiency-related Hodgkin lymphoma and its mimics.
    Said JW
    Adv Anat Pathol; 2007 May; 14(3):189-94. PubMed ID: 17452815
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epstein-Barr virus-specific cytotoxic T-lymphocytes for adoptive immunotherapy of post-transplant lymphoproliferative disease.
    Burns DM; Crawford DH
    Blood Rev; 2004 Sep; 18(3):193-209. PubMed ID: 15183903
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epstein-Barr virus-associated lymphoproliferative disorders.
    Ambinder RF
    Rev Clin Exp Hematol; 2003 Dec; 7(4):362-74. PubMed ID: 15129648
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epstein-Barr virus-associated lymphoproliferative disease after allogeneic haematopoietic stem cell transplantation: molecular monitoring and early treatment of high-risk patients.
    Meijer E; Cornelissen JJ
    Curr Opin Hematol; 2008 Nov; 15(6):576-85. PubMed ID: 18832928
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficiency of antiviral therapy plus IVIG in a case of primary EBV infection associated PTLD refractory to rituximab, chemotherapy, and antiviral therapy alone.
    Trappe R; Riess H; Anagnostopoulos I; Neuhaus R; Gärtner BC; Pohl H; Müller HP; Jonas S; Papp-Vary M; Oertel S
    Ann Hematol; 2009 Feb; 88(2):167-72. PubMed ID: 18636261
    [No Abstract]   [Full Text] [Related]  

  • 13. The Immune Response to Epstein Barr Virus and Implications for Posttransplant Lymphoproliferative Disorder.
    Martinez OM; Krams SM
    Transplantation; 2017 Sep; 101(9):2009-2016. PubMed ID: 28376031
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epstein-Barr virus lymphoproliferative disease after solid organ transplantation.
    Prockop SE; Vatsayan A
    Cytotherapy; 2017 Nov; 19(11):1270-1283. PubMed ID: 28965834
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Epstein-Barr virus and post-transplantation lymphoproliferations].
    Leblond V
    Ann Med Interne (Paris); 1997; 148(5):376-8. PubMed ID: 9538412
    [TBL] [Abstract][Full Text] [Related]  

  • 16. From Burkitt's lymphoma to chronic active Epstein-Barr virus (EBV) infection: an expanding spectrum of EBV-associated diseases.
    Okano M; Gross TG
    Pediatr Hematol Oncol; 2001; 18(7):427-42. PubMed ID: 11594706
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Severe Epstein-Barr virus infection in primary immunodeficiency and the normal host.
    Worth AJ; Houldcroft CJ; Booth C
    Br J Haematol; 2016 Nov; 175(4):559-576. PubMed ID: 27748521
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ganciclovir and the treatment of Epstein-Barr virus hepatitis.
    Adams LA; Deboer B; Jeffrey G; Marley R; Garas G
    J Gastroenterol Hepatol; 2006 Nov; 21(11):1758-60. PubMed ID: 16984606
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epstein-Barr virus: novel patented therapeutics.
    De Paoli P
    Expert Opin Ther Pat; 2010 Jun; 20(6):807-18. PubMed ID: 20384536
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Haematological associations of Epstein-Barr virus infection.
    Okano M
    Baillieres Best Pract Res Clin Haematol; 2000 Jun; 13(2):199-214. PubMed ID: 10942621
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.